Close
Group Leader: Dr Mark Linch
The work of the Urological Cancer Biology Group (UCBG) is aimed at translating high quality basic science into clinical care for patients with Prostate or Bladder Cancer. There are 3 main overlapping themes – to understand the genomic and inflammatory heterogeneity of urological cancer (Figure. 1), to define the signalling heterogeneity of urological cancers and to develop early phase, molecularly targeted translational clinical trials in urological malignancies.
Fig 1
Multiplexed immunohistochemistry for T-cell markers from 3 separate prostate regions in the same patient. Significant Tumour infiltrating lymphocytes are seen but with marked intratumoural heterogeneity.
